StockTipsArenaBeta

BUY Sun Pharmaceutical Industries Ltd. — BOB Capital Markets

BUYSun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries share price target & all analyst calls

byBOB Capital MarketsHorizon: NA (inferred 1 year)2 Nov 2026via Institutional / Brokerage Research

Entry₹1,770Inferred
Target₹2,046
Total upside +15.59%
Stop lossNot given
CMP₹1,8601d ago
Active+5.08%+10.00%upside left 12 mo left
Follow BOB Capital Markets for new calls(61% target hit, 366 closed calls)Get alertsWatch SUNPHARMA for new buy/sell callsGet alertsSee 22 other Long-term calls on SUNPHARMASee 541 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Nov, 5:27 pm IST
9 supporting7 neutral1 opposing
Supports the BUY call (9)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·6 Nov · yesterday

17 other SEBI-registered advisors have active long-term BUY calls on this stock, with 6 issued in the last 14 days

Advisor consensus · same horizon·2 Nov · 5d ago

Sun Pharma shares extend 4-day rally after USFDA approval for ILUMYA in arthritis patients

NewsCnbc-Tv18·30 Oct · 1w ago

(opens in new tab)

Sun Pharma received U.S. FDA approval for ILUMYA (tildrakizumab-asmm) to treat adults with active Psoriatic Arthritis, expanding the drug's market reach.

BSE · Company Update·30 Oct · 1w ago

(opens in new tab)

Sun Pharma's drug UNLOXCYT (cosibelimab-ipdl) received a Category 2A preferred designation in the updated NCCN guidelines for locally advanced cutaneous squamous cell carcinoma.

NSE · Press Release·20 Oct · 2w ago

(opens in new tab)
Neutral / worth noting (7)

Unaudited Financial Results for the quarter and half year ended 30 September 2026

NSE · Outcome of Board Meeting·30 Oct · 1w ago

(opens in new tab)

Sun Pharma to raise Rs 10,000 crore to part-finance Organon deal

NewsEt-Markets·21 Oct · 2w ago

(opens in new tab)

Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players

NewsEt-Markets·19 Oct · 3w ago

(opens in new tab)

CRISIL and ICRA have assigned ratings to the company's proposed non-convertible debenture programme and reaffirmed ratings on existing bank facilities and commercial paper.

BSE · Company Update·13 Oct · 3w ago

(opens in new tab)
Weighs against the BUY call (1)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Sun Pharmaceutical Industries

All analyst calls on Sun Pharmaceutical Industries

More from BOB Capital Markets

Every call and its outcome